AI assistant
Cellectar Biosciences, Inc. — Director's Dealing 2016
Dec 1, 2016
35021_dirs_2016-11-30_cfda0d77-79af-4143-8230-ea0a10f41724.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2016-11-29
Reporting Person: NEIS JOHN (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-11-29 | Common Stock, par value $0.00001 per share | P | 333333 | $1.49 | Acquired | 631317 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-11-29 | Series C Warrants (right to buy) | $1.50 | P | 333333 | Acquired | 2021-11-29 | Common Stock (333333) | Indirect |
Footnotes
F1: These securities are held by Venture Investors Early Stage fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership. VIESF IV GP LLC is the general partner of Venture Investors Early Stage Fund IV Limited Partnership and Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of VIESF IV GP LLC and Venture Investors LLC are made collectively by seven managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein.